Above and Beyond Research Team
The Above and Beyond team includes full-time staff, a scientific advisory board, and an extensive network of consultants. Meet some of our team below.
Scientific Advisory Board
Chair: Nicholas Boulis, MD
Dr. Boulis is director of the Gene and Cell Therapy for Neurorestoration Laboratory and an associate professor in the Emory Department of Neurosurgery. He has significant expertise in translational medicine, bridging the gap from proof-of-principle laboratory research to clinical trials and patient treatment. Dr. Boulis’s lab pursues novel and advanced treatments for ALS, as well as Parkinson’s Disease, Spinal Muscular Atrophy, and refractory pain conditions.
Raymond T Bartus, PhD
Dr. Bartus is a biotech executive scientist with extensive research, development, and operational experience. Through his career, Dr. Bartus has participated in the development of 15 pharmaceuticals and biologics that advanced into clinical trials, 6 of which received marketing approval. Dr. Bartus is also the co-originator of the “Cholinergic Hypothesis,” which led to the first four drugs approved for Alzheimer's disease. Dr. Bartus is now president of RTBioconsultants, Inc, a translational research consulting firm.
Robert P Bowser, PhD
As director of the ALS Research Center at Barrow Neurological Institute, Dr. Bowser leads research to determine the underlying mechanisms of ALS, identify new targets for drug treatment, and develop improved therapies for ALS treatment and clinical research studies. Dr. Bowser has contributed to ground-breaking efforts to discover and validate biomarkers for ALS. These biomarkers can be valuable diagnostic indicators of disease, predictors of disease progression, and measures of drug efficacy in clinical trials.
Jaimie M Henderson, MD
Dr. Henderson pioneered the development of image-guided neurosurgery and serves as director of the Stanford program in Stereotactic and Functional Neurosurgery. He is also co-director of the Stanford Neural Prosthetics Translational Laboratory and a leader for the BrainGate team, which both strive to provide functionally-useful neural prosthetics for people with paralysis. Dr. Henderson has surgically implanted investigational devices for a clinical trial to assess an intracortical neural interface system for patients with ALS, allowing them to type and communicate through the brain-computer interface.
Nicholas J Maragakis, MD
Dr. Maragakis is the Director of the ALS Center for Cell Therapy and Regeneration Research at Johns Hopkins and the Co-Director of the Johns Hopkins ALS Clinic. Dr. Maragakis’s research uses stem cell-derived motor neurons and glia to understand the development and propagation of ALS. His clinical research interests have included both multicenter clinical trials in ALS as well as investigator-initiated studies exploring the potential role of resistance and endurance exercise in ALS management.
Alexandre Betourne, PharmD, PhD, PMP
Chief Medical Officer
Dr. Betourne is an expert in neuroscience and pharmacology with over 15 years of research experience in both academic and biotech positions. He has extensive experience managing a diverse portfolio of projects, including small molecules and gene therapies for ALS. Dr. Betourne earned his PharmD and PhD from Toulouse University in France.
Diane Vandeputte, PharmD, PhD
Director Regulatory Affairs
Dr. Vandeputte brings over 20 years of industry experience in global regulatory affairs and pharmaceutical drug development with emphasis on CNS disorders. Dr. Vandeputte has in-depth knowledge of the legislative framework for rare neurological diseases. Prior to joining Above & Beyond she held roles of increasing responsibility in regulatory and medical affairs at PPD, Abbott, Solvay Pharmaceuticals and UCB. Dr. Vandeputte earned her PharmD and PhD from the University of Antwerp, Belgium.